Amgen, Inc. vs Invesco Galaxy Bitcoin ETF — how do they compare? Amgen, Inc. trades at $412.15 (market cap $224.14B), while Invesco Galaxy Bitcoin ETF trades at $63.04. The key difference: Amgen, Inc. pays a 2.43% dividend while Invesco Galaxy Bitcoin ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Invesco Galaxy Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | BTCO | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Crypto-linked |
52-Week High | $417.20 | $125.14 |
52-Week Low | $271.18 | $58.40 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →BTCO is a spot Bitcoin ETF that tracks the price of Bitcoin directly. It offers investors a regulated and convenient way to gain exposure to the digital currency through a traditional brokerage account without holding the asset.
Read more on BTCO →